Larger Clinical Studies Required To Assess Device Risk/Benefit – Duke’s Califf
This article was originally published in The Gray Sheet
Executive Summary
A rethinking of the U.S. clinical trials system is needed to truly understand the risks and benefits of current and future devices and drugs, Duke Clinical Research Institute Director Robert Califf, MD, asserted at the FDA Science Forum April 28